Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with NICE and the NHS on making the drug Sacituzumab Govitecan, also known as Trodelvy, available on the NHS in England.
The National Institute for Health and Care Excellence is currently appraising sacitizumab govitecan and expects to issue guidance in June 2022, with draft guidance expected in April 2022.